<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6DB65A5B-AE16-4085-BB3C-77EED6BDDE9D/chart/price-vs-fair-value?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6DB65A5B-AE16-4085-BB3C-77EED6BDDE9D/chart/price-vs-fair-value"/></p>
<p>納斯達克 GM:ANIP 1 年股價與公允價值</p>
<p>探索 ANI 製藥的社區公允價值並選擇您的觀點</p>
<p><strong>ANI Pharmaceuticals, Inc.</strong> (NASDAQ:ANIP) 的股票在過去一個月中繼續保持其近期的勢頭，漲幅達 25%。回顧更長時間，令人鼓舞的是，過去一年該股上漲了 41%。</p>
<p>即使在如此大幅的價格上漲之後，考慮到美國製藥行業幾乎一半的公司市銷率（&#34;P/S&#34;）超過 5.8 倍，甚至市銷率超過 18 倍的情況也並不罕見，ANI 製藥目前仍可能被視為一個強勁的買入機會，其市銷率為 2.2 倍。然而，我們需要更深入地挖掘，以確定這種大幅降低的市銷率是否有合理的基礎。</p>
<p>特朗普承諾要&#34;釋放&#34;美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
<p>查看我們對 ANI 製藥的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1528824-ps-multiple-vs-industry-1-dark-2/1754836260616?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1528824-ps-multiple-vs-industry-1-dark-2/1754836260616"/></p>
<p>納斯達克 GM:ANIP 市銷率與行業比較 2025 年 8 月 10 日</p>
<h3>ANI 製藥的表現如何</h3>
<p>ANI 製藥最近的表現確實不錯，其收入增長超過了大多數其他公司。一個可能性是，市銷率之所以較低，是因為投資者認為這種強勁的收入表現未來可能不那麼令人印象深刻。如果您喜歡這家公司，您會希望情況不是這樣，以便您可以在其不受歡迎時購買一些股票。</p>
<p>如果您想了解分析師對未來的預測，您應該查看我們對 ANI 製藥的 <strong>免費</strong> 報告。</p>
<h2>ANI 製藥是否有收入增長的預測？</h2>
<p>您唯一會真正感到舒適的情況是，當公司的增長明顯落後於行業時，才會看到像 ANI 製藥這樣低迷的市銷率。</p>
<p>如果我們回顧過去一年的收入增長，該公司實現了 39% 的可喜增長。強勁的近期表現意味着它在過去三年中總共實現了 197% 的收入增長。因此，我們可以首先確認該公司在這段時間內在收入增長方面做得很好。</p>
<p>展望未來，根據跟蹤該公司的八位分析師的預測，預計收入將在未來三年內每年增長 8.9%。與此同時，行業的其餘部分預計每年將增長 26%，這顯然更具吸引力。</p>
<p>根據這些信息，我們可以看到為什麼 ANI 製藥的市銷率低於行業水平。似乎大多數投資者預計未來增長有限，因此只願意為該股票支付較低的價格。</p>
<h2>最終結論</h2>
<p>ANI 製藥最近的股價上漲仍未使其市銷率與行業中位數相匹配。我們認為市銷率的作用主要不是作為估值工具，而是用來衡量當前投資者情緒和未來預期。</p>
<p>我們已經確定，ANI 製藥維持其低市銷率是因為其預測增長低於更廣泛的行業，正如預期的那樣。在這個階段，投資者認為收入改善的潛力不足以證明更高的市銷率。除非這些條件改善，否則它們將繼續在這些水平上形成股價的障礙。</p>
<p>在您採取下一步之前，您應該瞭解我們發現的 <strong>ANI 製藥的 1 個警告信號</strong>。</p>
<p>如果您對盈利的強勁公司感興趣，那麼您會想查看這份 <strong>免費</strong> 的有趣公司名單，這些公司交易的市盈率較低（但已證明它們能夠增長收益）。</p>

ANI制藥

<p>ANI 製藥公司（NASDAQ:ANIP）在過去一個月的股價上漲了 25%，在過去一年中上漲了 41%。儘管如此，該公司的市銷率（P/S）仍然較低，為 2.2 倍，而行業平均水平為 5.8 倍。分析師預測未來三年年均收入增長為 8.9%，遠低於行業的 26%。這種增長預期的差異導致了低市銷率，表明投資者對未來表現的懷疑。如果增長預期沒有改善，股價可能會保持受限</p>

<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6DB65A5B-AE16-4085-BB3C-77EED6BDDE9D/chart/price-vs-fair-value" alt="" original-src="https://images.simplywall.st/company/6DB65A5B-AE16-4085-BB3C-77EED6BDDE9D/chart/price-vs-fair-value"/></p>
<p>NasdaqGM:ANIP 1 Year Share Price vs Fair Value</p>
<div class="lb-trans"><p>納斯達克 GM:ANIP 1 年股價與公允價值</p>
</div><p>Explore ANI Pharmaceuticals's Fair Values from the Community and select yours</p>
<div class="lb-trans"><p>探索 ANI 製藥的社區公允價值並選擇您的觀點</p>
</div><p><strong>ANI Pharmaceuticals, Inc.</strong> (NASDAQ:ANIP) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a bit further, it's encouraging to see the stock is up 41% in the last year.</p>
<div class="lb-trans"><p><strong>ANI Pharmaceuticals, Inc.</strong> (NASDAQ:ANIP) 的股票在過去一個月中繼續保持其近期的勢頭，漲幅達 25%。回顧更長時間，令人鼓舞的是，過去一年該股上漲了 41%。</p>
</div><p>Even after such a large jump in price, ANI Pharmaceuticals may still look like a strong buying opportunity at present with its price-to-sales (or &#34;P/S&#34;) ratio of 2.2x, considering almost half of all companies in the Pharmaceuticals industry in the United States have P/S ratios greater than 5.8x and even P/S higher than 18x aren't out of the ordinary. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.</p>
<div class="lb-trans"><p>即使在如此大幅的價格上漲之後，考慮到美國製藥行業幾乎一半的公司市銷率（&#34;P/S&#34;）超過 5.8 倍，甚至市銷率超過 18 倍的情況也並不罕見，ANI 製藥目前仍可能被視為一個強勁的買入機會，其市銷率為 2.2 倍。然而，我們需要更深入地挖掘，以確定這種大幅降低的市銷率是否有合理的基礎。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承諾要&#34;釋放&#34;美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
</div><p>Check out our latest analysis for ANI Pharmaceuticals</p>
<div class="lb-trans"><p>查看我們對 ANI 製藥的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1528824-ps-multiple-vs-industry-1-dark-2/1754836260616" alt="" original-src="https://images.simplywall.st/asset/chart/1528824-ps-multiple-vs-industry-1-dark-2/1754836260616"/></p>
<p>NasdaqGM:ANIP Price to Sales Ratio vs Industry August 10th 2025</p>
<div class="lb-trans"><p>納斯達克 GM:ANIP 市銷率與行業比較 2025 年 8 月 10 日</p>
</div><h3>How ANI Pharmaceuticals Has Been Performing</h3>
<div class="lb-trans"><h3>ANI 製藥的表現如何</h3>
</div><p>ANI Pharmaceuticals certainly has been doing a good job lately as it's been growing revenue more than most other companies. One possibility is that the P/S ratio is low because investors think this strong revenue performance might be less impressive moving forward. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>ANI 製藥最近的表現確實不錯，其收入增長超過了大多數其他公司。一個可能性是，市銷率之所以較低，是因為投資者認為這種強勁的收入表現未來可能不那麼令人印象深刻。如果您喜歡這家公司，您會希望情況不是這樣，以便您可以在其不受歡迎時購買一些股票。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on ANI Pharmaceuticals.</p>
<div class="lb-trans"><p>如果您想了解分析師對未來的預測，您應該查看我們對 ANI 製藥的 <strong>免費</strong> 報告。</p>
</div><h2>Is There Any Revenue Growth Forecasted For ANI Pharmaceuticals?</h2>
<div class="lb-trans"><h2>ANI 製藥是否有收入增長的預測？</h2>
</div><p>The only time you'd be truly comfortable seeing a P/S as depressed as ANI Pharmaceuticals' is when the company's growth is on track to lag the industry decidedly.</p>
<div class="lb-trans"><p>您唯一會真正感到舒適的情況是，當公司的增長明顯落後於行業時，才會看到像 ANI 製藥這樣低迷的市銷率。</p>
</div><p>If we review the last year of revenue growth, the company posted a terrific increase of 39%. The strong recent performance means it was also able to grow revenue by 197% in total over the last three years. So we can start by confirming that the company has done a great job of growing revenue over that time.</p>
<div class="lb-trans"><p>如果我們回顧過去一年的收入增長，該公司實現了 39% 的可喜增長。強勁的近期表現意味着它在過去三年中總共實現了 197% 的收入增長。因此，我們可以首先確認該公司在這段時間內在收入增長方面做得很好。</p>
</div><p>Looking ahead now, revenue is anticipated to climb by 8.9% per annum during the coming three years according to the eight analysts following the company. Meanwhile, the rest of the industry is forecast to expand by 26% per annum, which is noticeably more attractive.</p>
<div class="lb-trans"><p>展望未來，根據跟蹤該公司的八位分析師的預測，預計收入將在未來三年內每年增長 8.9%。與此同時，行業的其餘部分預計每年將增長 26%，這顯然更具吸引力。</p>
</div><p>With this information, we can see why ANI Pharmaceuticals is trading at a P/S lower than the industry. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.</p>
<div class="lb-trans"><p>根據這些信息，我們可以看到為什麼 ANI 製藥的市銷率低於行業水平。似乎大多數投資者預計未來增長有限，因此只願意為該股票支付較低的價格。</p>
</div><h2>The Final Word</h2>
<div class="lb-trans"><h2>最終結論</h2>
</div><p>ANI Pharmaceuticals' recent share price jump still sees fails to bring its P/S alongside the industry median. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.</p>
<div class="lb-trans"><p>ANI 製藥最近的股價上漲仍未使其市銷率與行業中位數相匹配。我們認為市銷率的作用主要不是作為估值工具，而是用來衡量當前投資者情緒和未來預期。</p>
</div><p>We've established that ANI Pharmaceuticals maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected. At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.</p>
<div class="lb-trans"><p>我們已經確定，ANI 製藥維持其低市銷率是因為其預測增長低於更廣泛的行業，正如預期的那樣。在這個階段，投資者認為收入改善的潛力不足以證明更高的市銷率。除非這些條件改善，否則它們將繼續在這些水平上形成股價的障礙。</p>
</div><p>Before you take the next step, you should know about the <strong>1 warning sign for ANI Pharmaceuticals</strong> that we have uncovered.</p>
<div class="lb-trans"><p>在您採取下一步之前，您應該瞭解我們發現的 <strong>ANI 製藥的 1 個警告信號</strong>。</p>
</div><p>If strong companies turning a profit tickle your fancy, then you'll want to check out this <strong>free</strong> list of interesting companies that trade on a low P/E (but have proven they can grow earnings).</p>
<div class="lb-trans"><p>如果您對盈利的強勁公司感興趣，那麼您會想查看這份 <strong>免費</strong> 的有趣公司名單，這些公司交易的市盈率較低（但已證明它們能夠增長收益）。</p>
</div>

ANI 製藥公司（NASDAQ:ANIP）股價飆升 25%，但其低市銷率並不足以令人感到興奮